OncoTracker has years of experience accurately measuring soluble BCMA in the blood of thousands of multiple myeloma patients.
| WEST HOLLYWOOD, Calif., March 12, 2019 /PRNewswire/ -- OncoTracker, Inc. announced that it has strengthened its intellectual property portfolio in multiple myeloma by completing an agreement with the Institute for Myeloma and Bone Cancer Research to acquire worldwide rights to its intellectual property regarding both diagnostic testing and a new therapeutic approach for treating these patients. The first patent family includes a patent, titled “Diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and B-cell non-Hodgkin lymphoma,” that issued on November 13, 2018 (U.S. Patent No. US 10,126,301). This patent claims methods of assaying for BCMA (B-cell maturation antigen) in serum or other biological samples from patients with multiple myeloma. OncoTracker has years of experience accurately measuring soluble BCMA in the blood of thousands of multiple myeloma patients. The second patent family includes a patent application, titled, “Anti-cancer effects of JAK inhibitors in combination with lenalidomide and glucocorticoids,” that has recently received a notice of allowance from the U.S. Patent and Trademark Office (U.S. Patent Application No. 15/314,434). This allowed patent application relates to three approved drugs, ruxolitinib, lenalidomide and methylprednisolone or other glucocorticoids, that when administered restored responsiveness of a multiple myeloma patient to lenalidomide. At the American Society of Clinical Oncologist conference held in Chicago in June 2018, it was reported that 50% of multiple myeloma patients who had progressed from other therapies responded to such a drug regimen where notably all responding patients were refractory to lenalidomide. “We believe these two patents have profound clinical utility for multiple myeloma patients,” stated James R Berenson, MD, OncoTracker’s founder and Chief Scientist. “The patent covering a JAK inhibitor, administered with lenalidomide and glucocorticoids, has already been shown in a pilot clinical study to not only effectively treat multiple myeloma patients that have failed other therapies, but it also has been well tolerated.” “Assessment of blood levels of BCMA can more rapidly and accurately determine whether a multiple myeloma patient’s drug therapy is efficacious or not, which is of immense pharmacoeconomic value,” said James Kuo, MD, MBA, OncoTracker’s Chief Executive Officer. “We intend to establish partnerships with many other companies to commercial this patent and as well as the JAK inhibitor-related patent.” About OncoTracker: OncoTracker, Inc. is a West Hollywood-based oncology company with exclusive rights to a novel blood biomarker that is the target of several multiple myeloma therapies in clinical development. The company utilizes this biomarker to monitor the tumor burden and predict the therapeutic outcome of multiple myeloma patients. In addition, OncoTracker believes this biomarker has clinical relevancy in chronic lymphocytic leukemia, B-cell lymphoma and potentially other solid tumors. OncoTracker further possesses intellectual property related to two multiple myeloma therapies in clinical trials. Media Contacts: OncoTracker, Inc.
SOURCE OncoTracker |
View original content:
